Fueled by the promise of regenerative medicine, currently there is unprecedented interest in stem cells.
Furthermore, there have been revolutionary, but somewhat controversial, advances in our understanding of stem cell biology.
Stem cells likely play key roles in the repair of diverse lung injuries.
However, due to very low rates of cellular proliferation in vivo in the normal steady state, cellular and architectural complexity of the respiratory tract, and the lack of an intensive research effort, lung stem cells remain poorly understood compared to those in other major organ systems.
Ambient air-exposed lung is subject to an array of potentially damaging agents, including chemical oxidants and proteolytic enzymes.
Presumably, daily oxidant and protease wear and tear on structural components such as elastin and collagen contributes to inevitable age-related declines in pulmonary function in normal individuals.
Acute and chronic lung disease, or its treatment with oxygen and positive pressure ventilation, may further damage lung tissue in excess of the capacity for orderly repair, resulting in characteristic pathologic changes including tissue destruction or fibrotic scarring.
However, what determines the lungs' capacity for repair?
Certainly, one factor must be the ability of stem cells to proliferate and differentiate to replace damaged cells and tissues.
During development, self-renewing tissues are imbued with resident, tissue-specific stem cells, so-called adult somatic stem cells.
However, recent but highly controversial evidence suggests that stem cells from one type of tissue may generate cells typical of other organs.
In this fashion, circulating cells derived from bone marrow may augment resident stem cells.
Finally, there is great hope that embryonic stem cells, embryonic germ cells, or even adult somatic stem cells can be engineered as an unlimited source of cells to enhance organ-specific repair or replace lost tissues.
During embryonic development, the inner cell mass of the blastocyst forms three primary germ layers, which generate all fetal tissue lineages.
Embryonic stem cells (derived from the blastocyst inner cell mass), or embryonic germ cells (derived from the gonadal ridge), when cultured on embryonic mouse fibroblast feeder cell layers in the presence of a differentiation-suppressing cytokine (leukemia inhibitory factor), proliferate indefinitely and remain pluripotent.
Manipulation of culture conditions can coax the cells to undergo differentiation characteristic of many tissue types.
Theoretically, pluripotent embryonic cells can serve as an unlimited resource for therapeutic applications.
The traditional view of cell lineages is that adult somatic stem cells maintain cell populations in adult tissues.
The adult lung falls into the category in which cell proliferation is very low in the normal steady state but can be induced dramatically by injury.
The conditional nature of lung cell proliferation complicates the search for lung stem cells.
Cell compartments in the lung and functional integration
In the architecturally complex lung, cells of multiple germinal lineages interact both during morphogenesis and to maintain adult lung structure.
Even within derivatives of a single germ layer, cells become subdivided into separate cell lineage "zones".
For example, the endoderm generates least four distinct epithelial regions, each with a different cellular composition (Figure 1).
Additional cell types, including airway smooth muscle, fibroblasts, and the vasculature, are derived from mesoderm.
Airway and alveolar architecture, and in turn, function, result from interaction among epithelium, smooth muscle, fibroblasts, and vascular cells, all within an elaborate structural matrix of connective tissue.
The complexity of even this oversimplified view, which omits pulmonary neuroepithelial cells and bodies, innervations, and classical hematopoietically derived cells such as dendritic cells, mast cells, and macrophages, has hindered identification of lung stem cells and patterns of cell migration during tissue renewal.
Stem cell compartments in the lungs.
The endoderm-derived epithelium can be subdivided into at least four types whereas smooth muscle, fibroblasts, and vascular cells are derived from mesoderm.
The coordinated interaction of multiple cell types, including alveolar epithelium, interstitial fibroblasts, myofibroblasts and pulmonary endothelium, is necessary to form alveolar septa.
Stem cell plasticity and the lung
Recent studies challenge the view that tissues are maintained solely by organ-specific stem cells.
There is evidence that adult stem cells from a variety of sources can generate not only their own lineages, but also those of other tissues, sometimes crossing barriers of embryonic derivation previously thought impenetrable.
There are a few controversial reports that adult stem cells from outside the bone marrow may reconstitute the hematopoietic system, but most of the evidence flows in the other direction-namely, that cells from the bone marrow can generate diverse non-hematopoietic cell types.
Both experimental studies in animals and human clinical studies, provide evidence for, and against, circulatory delivery of lung progenitor cells.
While bone marrow-derived cells, such as alveolar macrophages, dendritic cells, mast cells, and lymphocytes, normally migrate to the lung, the surprise in the recent literature is that under certain circumstances circulating cells can apparently generate lung resident cells, including epithelial, endothelial, and myofibroblast cells.
Transplantation studies in mice can be performed using whole donor bone marrow, the fraction that adheres in culture, termed marrow stromal cells (MSC), or preparations enriched for hematopoietic stem cells (HSC).
Whole body irradiation, which may injure lung tissue, is typically used to deplete the host bone marrow.
Importantly, lung injury apparently enhances engraftment into lung.
Whole bone marrow, MSC, or HSC have all been reported to reconstitute lung parenchymal cells.
However, other investigators have identified only hematopoietic chimerism by HSCs.
Lung injury alone, without bone marrow transplantation, may promote stem cell migration.
For example, in the ovalbumin model of asthma, circulating fibrocytes were recruited into bronchial tissue, and in a bovine model of hypoxic pulmonary hypertension, cells capable of generating endothelial and smooth muscle cells in vitro were found in the circulation.
However, many questions remain unanswered.
The mechanism whereby cells assume lung cell phenotypes remains uncertain.
Several studies have demonstrated that cell fusion occurs both in vitro and in vivo, which likely explains why some of the cells contain both donor and lung cell markers.
Alternatively, cells may reprogram in the lung environment- a concept termed "transdifferentiation", which is defined as the ability of a particular cell from one tissue type to differentiate into a cell type characteristic of another tissue.
It has been suggested that many of the events previously attributed to transdifferentiation may actually represent cell fusions, particularly due to the influx of fusion-prone myeloid cells into damaged tissues from the repopulated bone marrow.
New, more stringent, criteria have been put forth for demonstration of transdifferentiation.
Bone marrow harbors a generalized pluripotent stem cell and the bone marrow cell responsible for lung engraftment has not been identified with certainty.
It is possible that rare transdifferentiation events represent migration of a pluripotent bone marrow cell type resembling an embryonic stem or embryonic germ cell still harbored in the adult bone marrow.
It remains unknown whether bone marrow cells must transit through an intermediate compartment before lung colonization or whether circulating stem cells can be mobilized from sources other than bone marrow.
It is important to note that bone marrow derived cells of typical hematopoietic lineage, chimeric cells created by fusion, or lung cells generated by transdifferentiation may all play a role in lung repair by promoting the local production of stem cells or reparative function of lung-specific cell types.
Lung "stem cell" diseases
Major lung diseases likely involving stem cells and the cellular targets for stem cell therapy are summarized in Table 1.
Major lung diseases potentially treatable by stem cell manipulation.
||Injured, Depleted, or Deranged Cellular Compartment*
|Congenital lung hypoplasia
Chronic lung disease of prematurity
|Alveolar epithelium, Interstitial fibroblast, Capillary endothelium
||Generate alveolar septa, Restore complex three dimensional structure
|Alveolar epithelium, Capillary endothelium
||Enhance surfactant production, Reinforce endothelial and epithelial barriers
||Alveolar epithelium, Interstitial fibroblast
||Prevent alveolar epithelial loss, Inhibit fibroblast proliferation
||Airway epithelium, Myofibroblasts, Airway smooth muscle
||Create an anti-inflammatory environment, Inhibit airway wall remodeling, Inhibit smooth muscle hypertrophy and hyperplasia
||Deliver functional CFTR
||Reinforce the epithelium against toxic, viral or immunologic injury
||Detection, monitoring or treatment based on molecular regulation of stem cell proliferation and differentiations
RDS - respiratory distress syndrome
CFTR - cystic fibrosis transmembrane conductance regulator
* each cell type listed in this column is affected in all of the specific conditions listed in the left hand column
These may be broadly categorized whether they involve stem cell deficiency, hyper-proliferation or possibly, a combination of both.
For example, impaired pulmonary endothelial and/or epithelial barrier function may contribute to the pathophysiology of adult respiratory distress syndrome.
Mobilization of endogenous endothelial or epithelial stem/progenitor cells or delivery of adult somatic stem cells, embryonic stem cells, or embryonic germ cells may theoretically improve barrier function, supporting the notion of treating a "stem cell deficiency".
Similarly, toxic, viral or alloimmune destruction of the bronchiolar epithelium suggests stem cell deficiency in bronchiolitis obliterans.
However, fibrotic reactions and scarring in response to epithelial injury can be viewed as fibroblast "stem cell hyper-proliferation".
The general concept is that augmentation of stem cells may minimize lung injury, augment repair, or possibly regenerate lost tissue.
However, one must also consider that inhibiting excessive growth of stem cells may be a valid therapeutic goal when hyper-proliferation contributes to disease pathophysiology, as in fibrosis, smooth muscle hyperplasia or lung cancer.
Challenges for lung regenerative medicine
What are the realistic prospects for beneficial stem cell therapy of the lung?
First, we must conclusively identify lung diseases/cases/timing in which cell and tissue damage occurs in excess of the capacity for timely endogenous repair.
Second, we must establish standardized sources of relevant stem/progenitor cells and methods for their delivery to the appropriate lung sub-compartment.
Once delivered, therapeutic cells must home to microscopic sites of need and integrate to serve a beneficial function.
There is clearly potential for adverse effects, as exemplified by the propensity of embryonic stem cells to form teratomas when implanted in vivo.
Major lung diseases potentially addressable by stem cell therapy may pose unique challenges.
Reversal of lung developmental anomalies resulting in hypoplasia, or repair of chronic lung disease of prematurity and advanced pulmonary emphysema in adults, will require neogenesis of alveolar septa in which the endogenous "tissue blueprint" never developed, or was completely destroyed.
Until we gain a much better understanding of lung tissue morphogenesis, we must rely on stem cells intrinsically "knowing" where to go and "how" to recreate alveolar septal architecture to ultimately restore higher order complex three dimensional relationships amongst alveoli, airways, and vessels.
Stem cell therapy to cure cystic fibrosis will require heterologous, or gene corrected autologous, stem cells to colonize the airway, proliferate, and differentiate into columnar cells covering a significant portion of the airway lumen.
However, most evidence thus far suggests that cells from the circulation may generate isolated, single airway basal cells.
Stem cell therapy to mitigate respiratory distress syndrome (RDS) will require cells capable of restoring alveolar endothelial and epithelial function in the face of evolving injury.
Whereas injury is thought to promote stem cell recruitment, the relevant question is whether it can occur quickly enough to meaningfully reverse acute, widespread cellular dysfunction typical of RDS.
Provocative, but controversial, recent evidence suggests that circulating stem cells may home to the lung.
There is great excitement and hope that exogenous and/or mobilized endogenous stem cells may be harnessed to prevent or treat acute and chronic lung diseases and even regenerate abnormally developed or lost tissue.
Our understanding of lung stem cells and the regulation of lung morphogenesis is still rudimentary, and the complex, integrated function of multiple cell types underlying normal lung structure and function poses unique challenges.
Thus, the therapeutic prospects for stem cell therapy in lungs appear more distant than in some other organs.
This realization should stimulate meaningful new studies from the lung research community.